Brokerage Firm Rating Update on Astrazeneca PLC (AZN)

Astrazeneca PLC (AZN) : Zacks Investment Research ranks Astrazeneca PLC (AZN) as 3, which is a Hold recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2.5, which indicates as a Buy.

Astrazeneca PLC (AZN) stock is expected to deviate a maximum of $1.8 from the average target price of $35.5 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $38 and the most muted being $34.


For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Argus Research upgrades its rating on Astrazeneca PLC (NYSE:AZN). The rating major has initiated the coverage with buy rating on the shares. Earlier, the shares were rated a Hold by the brokerage firm. The Analysts at Argus Research announces a current price target of $38 per share. The rating by the firm was issued on August 29, 2016.

Astrazeneca PLC (NYSE:AZN): The stock opened at $33.07 and touched an intraday high of $33.21 on Wednesday. During the day, the stock corrected to an intraday low of $32.96, however, the bulls stepped in and pushed the price higher to close in the green at $33.18 with a gain of 0.27% for the day. The total traded volume for the day was 4,487,444. The stock had closed at $33.09 in the previous trading session.

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *